|
CHANGES IN PLASMA BIOMARKER PANEL OF CARDIOVASCULAR RISK WITH BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS 1,* 1 2 1 2 2 1 JG b 1,* VF 1 2, S. Abramson 2 J Greenberg VFurer, J. Todd SAb , Q. A. Lu RR i M A J. Greenberg , V. Furer JTd QALu, R. Ramirez , M. Attur g 1NYU HOSPITAL FOR JOINT DISEASES New York 2Singulex, Alameda CA, United States 1NYU HOSPITAL FOR JOINT DISEASES,New York,Singulex,Alameda CA United States
It d ti Introduction Introduction Two large registries recently reported a beneficial effect of anti-TNF biologics on cardiovascular (CV) risk in RA. Yet Yet, the mechanism of CV risk reduction with anti-TNFs the mechanism of CV risk reduction with anti TNFs remains unclear.
Results The study cohort (n=60) included 33 anti-TNF drug starts (11 Th t d h t ( 60) i l d d 33 ti TNF d t (11 adalimumab, 18 etanercept, 4 infliximab) and 27 abatacept drug dli b18 tt4 iflii b)d27bt td tt 76% f (SD) f 52 (13) (T bl 76% were female, mean (SD) age of 52 (13) years (Table starts. 76% were female, mean (SD) age of 52 (13) years (Table starts. l 1). Blibi k llbtt t tdi Baseline biomarkers levels by treatment groups are presented in 1). Baseline biomarkers levels by treatment groups are presented in Table 2. Albilidifitdti Across all biologic drugs, significant reductions were observed for bdf DAS28 ESR d h CRP DAS28-ESR and hsCRP as expected. Other significant reductions tdOth i ifi t d ti bdfVEGFIL17F IL 6 d t t l MMP 9 were observed for VEGF, IL-17F, IL-6, proMMP-9, and total MMP-9 MMP 9
(T bl 3) Alth h th ff t i i d b t th ti TNF (Table 3). Although the effect size varied between the anti-TNF and d
abatacept groups, the only significant difference in drug effects was t th l i ifi t diff i d ff t
|
